# A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

> **NCT05873686** · PHASE1 · RECRUITING · sponsor: **Nuvectis Pharma, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Solid Tumor
- NSCLC (Non-small Cell Lung Cancer)
- Renal Cancer
- Mesothelioma
- Non-Small Cell Squamous Lung Cancer
- Non-small Cell Lung Adenocarcinoma

## Interventions

- **DRUG:** NXP900

## Key facts

- **NCT ID:** NCT05873686
- **Lead sponsor:** Nuvectis Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2027-03
- **Final completion:** 2027-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873686, "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05873686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*